The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 ...
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented ...
Kelun-Biotech has picked up another first for its TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan ...
MedPage Today on MSN
How Do GLP-1 Drugs Stack Up for Cardiorenal Benefits in Diabetes?
"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...
Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling a certain type of lung cancer, there’s good news.
Poster presentation: Title: Preclinical evaluation of petosemtamab, an epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor (LGR5) bispecific antibody, ...
Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The Netherlands and ...
SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT ...
Investing.com -- SystImmune, Inc. announced Monday it has received a $250 million milestone payment from Bristol Myers Squibb ...
Ficerafusp alfa is currently being evaluated in FORTIFI-HN01, a pivotal Phase 2/3 clinical trial in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback